Belco Pharma

Belco Pharma, established in 1975, is a WHO GMP-certified Indian pharmaceutical company specializing in the manufacturing and development of pharmaceutical formulations. The company offers a diverse portfolio of over 300 products across various dosage forms and therapeutic categories. Headquartered in Bahadurgarh, Haryana, India, Belco Pharma operates a state-of-the-art manufacturing facility equipped with advanced machinery, enabling it to cater to both domestic and international markets.

In January 2020, Belco Pharma Private Limited was incorporated with the Corporate Identification Number (CIN) U74999DL2020PTC360147. The company is privately held, with authorized capital of ₹1.00 million and paid-up capital of ₹0.10 million. As of the latest available data, Belco Pharma employs approximately 104 individuals, reflecting a 14% increase in workforce size over the past year.

Belco Pharma's manufacturing facility is strategically located in Bahadurgarh, Haryana, on the periphery of New Delhi, India's capital. This plant is equipped with modern machinery and adheres to stringent quality control measures, ensuring the production of high-quality pharmaceutical formulations. The facility's capabilities encompass the manufacturing of tablets, capsules, syrups, injections, and other dosage forms, catering to a wide range of therapeutic categories.

The leadership team at Belco Pharma includes:

• Kapil Singla: Director since January 10, 2020.

• Puneet Singla: Director since January 10, 2020.

The company's leadership is committed to maintaining high standards of quality and competitiveness in the pharmaceutical industry.

Belco Pharma has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, facilitating market access and distribution. Belco Pharma's adherence to international quality standards and regulatory requirements has enabled it to expand its footprint in these markets.

Belco Pharma has made strategic inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality and affordability has facilitated its entry into these regions. Additionally, Belco Pharma's products are registered in 25 countries worldwide, reflecting its global outreach and the trust placed in its offerings.

Belco Pharma's geographic strategy focuses on diversification and risk mitigation by expanding its presence across various international markets. The company's strategic tie-ups and joint ventures with multinational and national companies have bolstered its market position. By catering to both domestic and international markets, Belco Pharma aims to achieve sustainable growth and reduce dependence on any single market.

Belco Pharma has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with FDA regulations. The company has also filed Abbreviated New Drug Applications (ANDAs) for its generic products, facilitating market entry in the U.S. Belco Pharma's commitment to quality and regulatory compliance is evident in its FDA-approved Drug Master Files (DMFs), which detail the manufacturing processes and quality controls for its products. The company's facilities have undergone FDA inspections, reflecting its adherence to international standards.

Belco Pharma's manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practices (WHO GMP), ensuring that its products meet international quality standards. The company has also obtained European Union Good Manufacturing Practice (EU GMP) certificates, facilitating access to the European market. These certifications underscore Belco Pharma's commitment to producing high-quality pharmaceutical formulations.

In India, Belco Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), authorizing it to produce pharmaceutical formulations. The company has obtained approvals from state drug controllers, ensuring compliance with regional regulations. Belco Pharma has also secured export No Objection Certificates (NOCs), facilitating the export of its products to various international markets.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Belco Pharma by regulatory authorities. This absence suggests that the company maintains a strong compliance record with regulatory agencies.

Belco Pharma operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not publicly disclosed, the company's focus on quality, affordability, and regulatory compliance positions it favorably against competitors. Belco Pharma's strategic partnerships and diverse product portfolio further enhance its competitive edge.

Belco Pharma's key differentiators include its extensive product portfolio of over 300 pharmaceutical formulations, adherence to international quality standards such as WHO GMP and EU GMP, and strategic collaborations with multinational and national companies. The company's commitment to providing quality medicines at reasonable prices underscores its dedication to patient well-being.

Belco Pharma's current strategic direction focuses on expanding its presence in both generics and branded generics segments. The company's emphasis on research and development enables it to introduce new products and delivery systems, enhancing patient compliance. Looking ahead, Belco Pharma aims to strengthen its position in existing markets and explore new business opportunities to achieve sustainable growth.

Belco Pharma has demonstrated a consistent track record in pharmaceutical manufacturing, with an estimated annual revenue of $20.9 million and a workforce of approximately 104 employees. The company's export volume and consistency are evident in its registration of over 200 products in 25 countries worldwide. Belco Pharma's commitment to quality and regulatory compliance enhances its reliability as a supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the facility's registration with the U.S. Food and Drug Administration.

• WHO GMP Certification: Ensure the manufacturing facility holds a valid WHO GMP certificate.

• EU GMP Certification: Verify the presence of an EU GMP certificate for the facility.

• ISO Certification: Check for relevant ISO certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting copies directly from Belco Pharma.

Importers should undertake the following steps to ensure a thorough evaluation of Belco Pharma:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO GMP, EU GMP, and ISO certifications.

• Assess Manufacturing Facilities: Evaluate the facility's compliance with international quality standards and its capacity to meet order requirements.

• Review Financial Statements: Analyze recent financial statements to assess the company's financial health and stability.

• Check References: Obtain feedback from existing clients and partners regarding product quality and reliability.

• Inspect Product Samples: Request samples to evaluate product quality and consistency.

Red flags to watch for include expired or invalid certifications, discrepancies in financial records, and negative feedback from references. Recommended pre-order checks involve conducting factory audits and reviewing quality control processes to ensure alignment with importers' standards.